Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DNTH Stock Forecast 2026-2027
$80.32
Current Price
$3.47B
Market Cap
Buy 13
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DNTH Price Targets
+149.0%
To High Target of $200.00
+53.1%
To Median Target of $123.00
-0.4%
To Low Target of $80.00
DNTH Price Momentum
+23.2%
1 Week Change
+69.5%
1 Month Change
+277.4%
1 Year Change
+94.9%
Year-to-Date Change
-8.7%
From 52W High of $88.02
+500.7%
From 52W Low of $13.37
📊 TOP ANALYST CALLS
Did DNTH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Magenta is one of their latest high-conviction picks.
Latest DNTH Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, DNTH has a bullish consensus with a median price target of $123.00 (ranging from $80.00 to $200.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $80.32, the median forecast implies a 53.1% upside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yatin Suneja at Guggenheim, projecting a 149.0% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 0.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DNTH Analyst Ratings
13
Buy
0
Hold
0
Sell
DNTH Price Target Range
Low
$80.00
Average
$123.00
High
$200.00
Current: $80.32
Latest DNTH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DNTH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $103.00 |
| Mar 10, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $80.00 |
| Mar 10, 2026 | Clear Street | Bill Maughan | Buy | Maintains | $130.00 |
| Mar 10, 2026 | Baird | Joel Beatty | Outperform | Maintains | $132.00 |
| Mar 10, 2026 | Raymond James | Steven Seedhouse | Strong Buy | Upgrade | $123.00 |
| Mar 9, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $110.00 |
| Mar 9, 2026 | Oppenheimer | Leland Gershell | Outperform | Maintains | $145.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $130.00 |
| Mar 4, 2026 | Guggenheim | Yatin Suneja | Buy | Maintains | $200.00 |
| Feb 11, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $55.00 |
| Feb 2, 2026 | Jefferies | Maury Raycroft | Buy | Maintains | $81.00 |
| Jan 8, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $63.00 |
| Dec 22, 2025 | Wedbush | Laura Chico | Outperform | Reiterates | $46.00 |
| Nov 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $47.00 |
| Nov 6, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $46.00 |
| Oct 14, 2025 | Truist Securities | Danielle Brill | Buy | Initiates | $56.00 |
| Sep 17, 2025 | Clear Street | Bill Maughan | Buy | Initiates | $100.00 |
| Sep 12, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $44.00 |
| Sep 12, 2025 | Stifel | Alex Thompson | Buy | Maintains | $65.00 |
| Sep 9, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $100.00 |
Dianthus Therapeutics Inc. (DNTH) Competitors
The following stocks are similar to Magenta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dianthus Therapeutics Inc. (DNTH) Financial Data
Dianthus Therapeutics Inc. has a market capitalization of $3.47B with a P/E ratio of 3.3x. The company generates $2.04M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -78.6% quarter-over-quarter, while maintaining an operating margin of -24,486.3% and return on equity of -38.4%.
Valuation Metrics
Market Cap
$3.47B
Enterprise Value
$3.17B
P/E Ratio
3.3x
PEG Ratio
0.1x
Price/Sales
1,705.1x
Growth & Margins
Revenue Growth (YoY)
-78.6%
Gross Margin
N/A
Operating Margin
-24,486.3%
Net Margin
0.0%
EPS Growth
-81.8%
Financial Health
Cash/Price Ratio
+11.3%
Current Ratio
13.3x
Debt/Equity
0.3x
ROE
-38.4%
ROA
-24.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Dianthus Therapeutics Inc. (DNTH) Business Model
About Dianthus Therapeutics Inc.
What They Do
Develops precision medicines for autoimmune diseases.
Business Model
The company generates revenue through the discovery and development of targeted therapies, utilizing monoclonal antibodies to treat severe autoimmune and inflammatory diseases. Dianthus Therapeutics partners with research institutions and other organizations to advance its innovative treatment options and bring them to market, addressing significant unmet medical needs.
Additional Information
Dianthus Therapeutics is positioned within the biotechnology sector and plays a vital role in the pharmaceutical industry by focusing on novel therapeutic solutions. Their mission emphasizes improving patient outcomes and transforming standards of care for those suffering from complex health conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
78
CEO
Mr. Marino Garcia M.B.A.
Country
United States
IPO Year
2018
Website
dianthustx.comDianthus Therapeutics Inc. (DNTH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of 0.00% and -112.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Mar 04, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Dianthus Therapeutics closed a public offering of 8.47 million shares at $81 each, raising approximately $719 million. The offering included pre-funded warrants for additional shares.
Why It Matters
Dianthus Therapeutics raised approximately $719 million through a public offering, strengthening its financial position for developing autoimmune therapies, potentially enhancing investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dianthus Therapeutics stock rose after the company announced progress on its experimental treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Why It Matters
Dianthus Therapeutics' stock surge indicates positive market sentiment and potential for future revenue from its CIDP treatment, signaling growth prospects for investors.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
Dianthus Therapeutics will hold a conference call on March 9, 2026, to discuss interim results from the Phase 3 CAPTIVATE trial of claseprubart for treating CIDP.
Why It Matters
The upcoming conference call on interim results from a Phase 3 trial could significantly impact Dianthus Therapeutics' stock price, reflecting investors' expectations for the drug's potential success.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A preliminary GO decision was made in the CAPTIVATE trial, achieving 20 confirmed responders with under 40 participants, ahead of Q2'26 guidance.
Why It Matters
The early GO decision in CAPTIVATE indicates strong efficacy and potential market viability, influencing stock performance and investor sentiment ahead of Q2'26 guidance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CIDP is a rare autoimmune disorder affecting peripheral nerves, leading to muscle weakness, numbness, and sensory loss for over 8 weeks.
Why It Matters
CIDP's impact on healthcare demand may drive investments in biotech and pharma sectors focused on autoimmune treatments, influencing stock performance and market trends.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Dianthus Therapeutics, Inc. (DNTH) reported a quarterly loss of $1.43 per share, exceeding the Zacks estimate of a $0.98 loss, and worsening from a $0.81 loss per share a year earlier.
Why It Matters
Dianthus Therapeutics' larger-than-expected quarterly loss raises concerns about its financial health and operational efficiency, potentially impacting stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About DNTH Stock
What is Dianthus Therapeutics Inc.'s (DNTH) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Dianthus Therapeutics Inc. (DNTH) has a median price target of $123.00. The highest price target is $200.00 and the lowest is $80.00.
Is DNTH stock a good investment in 2026?
According to current analyst ratings, DNTH has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $80.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DNTH stock?
Wall Street analysts predict DNTH stock could reach $123.00 in the next 12 months. This represents a 53.1% increase from the current price of $80.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dianthus Therapeutics Inc.'s business model?
The company generates revenue through the discovery and development of targeted therapies, utilizing monoclonal antibodies to treat severe autoimmune and inflammatory diseases. Dianthus Therapeutics partners with research institutions and other organizations to advance its innovative treatment options and bring them to market, addressing significant unmet medical needs.
What is the highest forecasted price for DNTH Dianthus Therapeutics Inc.?
The highest price target for DNTH is $200.00 from Yatin Suneja at Guggenheim, which represents a 149.0% increase from the current price of $80.32.
What is the lowest forecasted price for DNTH Dianthus Therapeutics Inc.?
The lowest price target for DNTH is $80.00 from Laura Chico at Wedbush, which represents a -0.4% decrease from the current price of $80.32.
What is the overall DNTH consensus from analysts for Dianthus Therapeutics Inc.?
The overall analyst consensus for DNTH is bullish. Out of 22 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $123.00.
How accurate are DNTH stock price projections?
Stock price projections, including those for Dianthus Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 9:22 AM UTC